Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia

被引：9
作者：
Vivian G. Oehler
Jerald P. Radich
机构：
[1] Clinical Research Division, Program in Genetics and Genomics, F. Hutchinson Cancer Research Center, Seattle, WA 98109
来源：
Current Oncology Reports | 2003年 / 5卷 / 5期
关键词：
Imatinib; Chronic Myeloid Leukemia; Chronic Myelogenous Leukemia; Minimal Residual Disease; Imatinib Mesylate;
D O I：
10.1007/s11912-003-0030-x
中图分类号：
学科分类号：
摘要：
The elucidation of the molecular biology of chronic myeloid leukemia (CML) has provided a paradigm for understanding leukemogenesis, targeted drug development, and disease monitoring at the molecular level. Minimal residual disease (MRD) monitoring by fluorescence in situ hybridization and polymerase chain reaction (PCR) has become an important tool in predicting relapso after allogeneic transplant, allowing for early intervention strategies such as donor lymphocyte infusion. MRD monitoring is important for assessment of disease status in patients who obtain a complete cytogenetic remission, and this approach is likely to play an important role in following patients to determine who will relapse on imatinib mesylate therapy. This review focuses primarily on MRD monitoring by PCR. Copyright © 2003 by Current Science Inc.
引用
收藏
页码：426 / 435
页数：9
相关论文
共 79 条
[1]  
Hansen J.A., Gooley T.A., Martin P.J., Et al., Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia, N. Engl. J. Med., 338, pp. 962-968, (1998)
[2]  
O'Brien S.G., Guilhot F., Larson R.A., Et al., Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia, N. Engl. J. Med., 348, pp. 994-1004, (2003)
[3]  
Druker B.J., O'Brien S.G., Cortes J., Chronic myelogenous leukemia, American Society for Hematology Education Book, pp. 111-135, (2002)
[4]  
Talpaz M., Silver R.T., Druker B.J., Et al., Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study, Blood, 99, pp. 1928-1937, (2002)
[5]  
Sawyers C.L., Hochhaus A., Feldman E., Et al., Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study, Blood, 99, pp. 3530-3539, (2002)
[6]  
Diamond J., Goldman J.M., Melo J.V., BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia, Blood, 85, pp. 2171-2175, (1995)
[7]  
Melo J.V., The molecular biology of chronic myeloid leukaemia, Leukemia, 10, pp. 751-756, (1996)
[8]  
Shepherd P., Suffolk R., Halsey J., Allan N., Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: No correlation with clinical features, cytogenetic response, duration of chronic phase, or survival, Br. J. Haematol., 89, pp. 546-554, (1995)
[9]  
Faderl S., Talpaz M., Estrov Z., Et al., The biology of chronic myeloid leukemia, N. Engl. J. Med., 341, pp. 164-172, (1999)
[10]  
Hermans A., Heisterkamp N., von Linden M., Et al., Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia, Cell, 51, pp. 33-40, (1987)
12345678